Antibodies to Cytomegalovirus and Herpes Simplex Virus 1 Associated with Cognitive Function in Schizophrenia

Overview

Journal Schizophr Res

Specialty Psychiatry

Date 2008 Sep 20

PMID 18801645

Citations 50

Authors

Brian H Shirts

Konasale M Prasad

Michael F Pogue-Geile

Faith Dickerson

Robert H Yolken

Vishwajit L Nimgaonkar

Affiliations

Soon will be listed here.

Abstract

Background: Cognitive impairment in the form of decreased working memory and executive functions has been recognized as a key deficit in schizophrenia. Neurotropic viruses have been associated with focal gray matter deficits in patients with schizophrenia. We evaluated whether such agents alter cognitive function in schizophrenia.

Methods: The sample consisted of 329 patients diagnosed with schizophrenia or schizoaffective disorder. We evaluated associations between exposure to selected agents (Herpes Simplex Viruses 1 and 2 (HSV1, HSV2 respectively) cytomegalovirus (CMV) and Toxoplasma gondii) and scores on the Trail Making Test (TMT), controlling for relevant variables.

Results: Serological evidence of exposure to CMV was associated with impaired performance on TMT part A time to completion (p=0.044), a measure of visual search, working memory, and psychomotor speed. Both CMV and HSV1 were significantly associated with increased errors on TMT part B (p<0.001 for both viruses). HSV2 and T. gondii exposure measures were not associated with any of the cognitive functions evaluated using TMT.

Conclusions: Both CMV and HSV1 are associated with impaired cognitive function in schizophrenia as measured by the TMT. Further analyses to evaluate the impact of other illness related variables including genetic variants are warranted.

Citing Articles

Latent toxoplasmosis, Cytomegalovirus, and Herpes Simplex Virus infections and risk of motorcycle accidents: A case-control study in a county with a high rate of motorcycle injuries in Iran.

Rayatdoost E, Chegin M, Taghipour A, Shadmand E, Rezaei F, Falahi S PLoS One. 2024; 19(8):e0307950.

PMID: 39172983 PMC: 11341033. DOI: 10.1371/journal.pone.0307950.

Human Cytomegalovirus Infection and Neurocognitive and Neuropsychiatric Health.

Gale S, Farrer T, Erbstoesser R, MacLean S, Hedges D Pathogens. 2024; 13(5).

PMID: 38787269 PMC: 11123947. DOI: 10.3390/pathogens13050417.

Pharmacological management of neurocognitive impairment in schizophrenia: A narrative review.

Arsenault-Mehta K, Hochman-Berard M, Johnson A, Semenova D, Nguyen B, Willis J Neuropsychopharmacol Rep. 2023; 44(1):2-16.

PMID: 37794723 PMC: 10932777. DOI: 10.1002/npr2.12382.

Indicators of HSV1 Infection, ECM-Receptor Interaction, and Chromatin Modulation in a Nuclear Family with Schizophrenia.

Huang Y, Ping L, Hsu S, Tsai H, Cheng M J Pers Med. 2023; 13(9).

PMID: 37763159 PMC: 10532901. DOI: 10.3390/jpm13091392.

Serologic evaluation of cytomegalovirus (CMV), Toxoplasma gondii and Brucella in schizophrenia patients.

Banihashem S, Yousefi Saber F, Motazedian S, Mardani M, Shamsi A, Nazari M Caspian J Intern Med. 2023; 14(3):560-566.

PMID: 37520870 PMC: 10379783. DOI: 10.22088/cjim.14.3.560.

References

Shirts B, Wood J, Yolken R, Nimgaonkar V . Comprehensive evaluation of positional candidates in the IL-18 pathway reveals suggestive associations with schizophrenia and herpes virus seropositivity. Am J Med Genet B Neuropsychiatr Genet. 2007; 147(3):343-50. DOI: 10.1002/ajmg.b.30603. View

Arbuthnott K, Frank J . Trail making test, part B as a measure of executive control: validation using a set-switching paradigm. J Clin Exp Neuropsychol. 2000; 22(4):518-28. DOI: 10.1076/1380-3395(200008)22:4;1-0;FT518. View

ODonnell B . Cognitive impairment in schizophrenia: a life span perspective. Am J Alzheimers Dis Other Demen. 2007; 22(5):398-405. PMC: 10846246. DOI: 10.1177/1533317507304745. View

Dalman C, Allebeck P, Gunnell D, Harrison G, Kristensson K, Lewis G . Infections in the CNS during childhood and the risk of subsequent psychotic illness: a cohort study of more than one million Swedish subjects. Am J Psychiatry. 2007; 165(1):59-65. DOI: 10.1176/appi.ajp.2007.07050740. View

Heaton R, Paulsen J, McAdams L, Kuck J, Zisook S, Braff D . Neuropsychological deficits in schizophrenics. Relationship to age, chronicity, and dementia. Arch Gen Psychiatry. 1994; 51(6):469-76. DOI: 10.1001/archpsyc.1994.03950060033003. View

Wang H, Wang G, Li Q, Shu C, Jiang M, Guo Y . Prevalence of Toxoplasma infection in first-episode schizophrenia and comparison between Toxoplasma-seropositive and Toxoplasma-seronegative schizophrenia. Acta Psychiatr Scand. 2006; 114(1):40-8. DOI: 10.1111/j.1600-0447.2006.00780.x. View

Endicott J, Spitzer R, Fleiss J, Cohen J . The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry. 1976; 33(6):766-71. DOI: 10.1001/archpsyc.1976.01770060086012. View

Savla G, Moore D, Roesch S, Heaton R, Jeste D, Palmer B . An evaluation of longitudinal neurocognitive performance among middle-aged and older schizophrenia patients: use of mixed-model analyses. Schizophr Res. 2006; 83(2-3):215-23. DOI: 10.1016/j.schres.2005.12.851. View

Shirts B, Kim J, Reich S, Dickerson F, Yolken R, Devlin B . Polymorphisms in MICB are associated with human herpes virus seropositivity and schizophrenia risk. Schizophr Res. 2007; 94(1-3):342-53. DOI: 10.1016/j.schres.2007.04.021. View

10.

Talkowski M, Kirov G, Bamne M, Georgieva L, Torres G, Mansour H . A network of dopaminergic gene variations implicated as risk factors for schizophrenia. Hum Mol Genet. 2007; 17(5):747-58. PMC: 3777405. DOI: 10.1093/hmg/ddm347. View

11.

Hyde T, Nawroz S, Goldberg T, BIGELOW L, Strong D, Ostrem J . Is there cognitive decline in schizophrenia? A cross-sectional study. Br J Psychiatry. 1994; 164(4):494-500. DOI: 10.1192/bjp.164.4.494. View

12.

Potvin S, Stip E, Sepehry A, Gendron A, Bah R, Kouassi E . Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry. 2007; 63(8):801-8. DOI: 10.1016/j.biopsych.2007.09.024. View

13.

Ashley R, Wu L, Pickering J, Tu M, Schnorenberg L . Premarket evaluation of a commercial glycoprotein G-based enzyme immunoassay for herpes simplex virus type-specific antibodies. J Clin Microbiol. 1998; 36(1):294-5. PMC: 124858. DOI: 10.1128/JCM.36.1.294-295.1998. View

14.

Koponen H, Rantakallio P, Veijola J, Jones P, Jokelainen J, Isohanni M . Childhood central nervous system infections and risk for schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2004; 254(1):9-13. DOI: 10.1007/s00406-004-0485-2. View

15.

Aiello A, Haan M, Blythe L, Moore K, Gonzalez J, Jagust W . The influence of latent viral infection on rate of cognitive decline over 4 years. J Am Geriatr Soc. 2006; 54(7):1046-54. DOI: 10.1111/j.1532-5415.2006.00796.x. View

16.

Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R . C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr Res. 2007; 93(1-3):261-5. DOI: 10.1016/j.schres.2007.03.022. View

17.

Leweke F, Gerth C, Koethe D, Klosterkotter J, Ruslanova I, Krivogorsky B . Antibodies to infectious agents in individuals with recent onset schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2004; 254(1):4-8. DOI: 10.1007/s00406-004-0481-6. View

18.

Stuss D, Bisschop S, Alexander M, Levine B, Katz D, Izukawa D . The Trail Making Test: a study in focal lesion patients. Psychol Assess. 2001; 13(2):230-9. View

19.

Green M, Kern R, Braff D, Mintz J . Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?. Schizophr Bull. 2001; 26(1):119-36. DOI: 10.1093/oxfordjournals.schbul.a033430. View

20.

Shibuya-Tayoshi S, Sumitani S, Kikuchi K, Tanaka T, Tayoshi S, Ueno S . Activation of the prefrontal cortex during the Trail-Making Test detected with multichannel near-infrared spectroscopy. Psychiatry Clin Neurosci. 2007; 61(6):616-21. DOI: 10.1111/j.1440-1819.2007.01727.x. View